Philpott CM, Erskine S, Hopkins C, et al.The global allergy and asthma European network (GALEN) rhinosinusitis cohort: a large European cross‐sectional study of chronic rhinosinusitis patients with and without nasal polyps. Nasal and sinus symptoms and chronic rhinosinusitis in a population‐based sample. Hirsch AG, Stewart WF, Sundaresan AS, et al.Chronic rhinosinusitis in Europe–an underestimated disease. Hastan D, Fokkens WJ, Bachert C, et al.įigure: Indications for biological treatment in patients with CRSwNP: proposal of the multidisciplinary EUFOREA Expert Board Meeting (Modified from Fokkens et al ) It is likely that biologics will become a valid alternative to sinus surgery. They have put forward 5 criteria for careful selection of patients to whom biologics should be prescribed (see Figure), as well as criteria to define the response to biological therapy after 1 year. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organised a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into care pathways for CRSwNP patients with and without comorbid asthma. Ĭareful selection of patients is highly recommended. The first studies with these biologics in CRSwNP have shown promising results and a positive impact on quality of life. Omalizumab and other biologics (anti-IL5, anti-IL5R, and anti-Il4Rα) are effective for the treatment of asthma with a type 2 inflammatory signature. However, type 2 inflammation-targeting biologics have entered the market for selected pheno/endotypes of asthma and may soon become available for CRSwNP patients. The goal of CRSwNP management is clinical control with minimal use of medication or surgery, but this is challenging. When symptoms are persistent or when there is a long-term need for antibiotics or systemic steroids, it is considered uncontrolled disease. ĬRSwNP severely impacts quality of life and has a significant burden on society. It is frequently comorbid with asthma and both diseases share common underlying pathophysiological mechanisms driving the disease, including type 2 inflammation. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the sinonasal cavities.
0 kommentar(er)
